Literature DB >> 33264034

Contribution of long noncoding RNA HOTAIR variants to preeclampsia susceptibility in Iranian women.

Sahra Esmkhani1, Hossein Sadeghi2, Majid Ghasemian3, Reihaneh Pirjani4, Mona Amin-Beidokhti5, Milad Gholami6, Fakhrolmolouk Yassaee7, Reza Mirfakhraie5.   

Abstract

Objective: To investigate the possible association of lncRNA HOTAIR rs920778 and rs874945 polymorphisms with preeclampsia risk in a sample from the Iranian population. Method: The study subjects included 250 preeclamptic women and 250 healthy women. The genotyping for rs920778 and rs874945 polymorphisms were performed using the TP-ARMS-PCR method.
Results: HOTAIR rs920778 increased the risk of preeclampsia under the dominant and recessive inheritance patterns (OR = 4.84, 95% CI: 3.30-7.10, P < 0.0001; OR = 6.86, 95% CI: 3.51-13.42, P < 0.0001; respectively).
Conclusion: This study confirmed the association of HOTAIR rs920778 polymorphism with preeclampsia in Iranian women. Further studies should be performed to confirm our findings.

Entities:  

Keywords:  HOTAIR ; Preeclampsia; genetic association study; long noncoding-RNA; single nucleotide polymorphism

Year:  2020        PMID: 33264034     DOI: 10.1080/10641955.2020.1855192

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  2 in total

Review 1.  Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders.

Authors:  Majid Ghasemian; Masoumeh Rajabibazl; Unes Sahebi; Samira Sadeghi; Reza Maleki; Veys Hashemnia; Reza Mirfakhraie
Journal:  Cancer Cell Int       Date:  2022-06-17       Impact factor: 6.429

2.  Association of Polymorphisms within HOX Transcript Antisense RNA (HOTAIR) with Type 2 Diabetes Mellitus and Laboratory Characteristics: A Preliminary Case-Control Study.

Authors:  Saman Sargazi; Mahdiyeh Ravanbakhsh; Milad Heidari Nia; Shekoufeh Mirinejad; Roghayeh Sheervalilou; Mahdi Majidpour; Hiva Danesh; Ramin Saravani
Journal:  Dis Markers       Date:  2022-03-22       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.